Felipe Azeka

Mr. Felipe Azeka

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 October 2026 in Einstein (São Paulo)
Verified
Journal Article
Open access
PDF file
ISIsadora Biazon de Souza
Isadora Biazon de Souza
LMLarissa Mikalauskas
Larissa Mikalauskas
FAFelipe Azeka
Felipe Azeka
AFAlexander de Moraes Frankiw
Alexander de Moraes Frankiw
NGNathan Mignella Greco
Nathan Mignella Greco
AFAlessandra Faria
Alessandra Faria

24 June 2026 in Muscles
Verified
Journal Article
Open access
PDF file
FAFelipe Azeka
Felipe Azeka
PSPaulo de Lima Serrano
Paulo de Lima Serrano
DSDaniel Delgado Seneor
Daniel Delgado Seneor
SCSophia Calegaretti
Sophia Calegaretti
MPMateus Medeiros Pinheiro
Mateus Medeiros Pinheiro
Paulo Victor Sgobbi SouzaPaulo Victor Sgobbi Souza
Paulo Victor Sgobbi Souza
Congenital Myasthenic Syndrome represents a complex and heterogeneous group of inherited neuromuscular disorders, which result from variants in genes involved in different pathophysiological mechanisms related to the neuromuscular junction. LRP4 (Low-density lipoprotein receptor-related protein 4) represents one of the most important proteins involved in this complex signaling pathway, acting in a complex with agrin and Muscle Skeletal Receptor Tyrosine Kinase (MuSK) proteins. LRP4 became known to most neurologists due to the description of anti-LRP4 antibody-related Myasthenia Gravis. There are, however, different neurological and neuromuscular disorders that result from pathogenic variants in LRP4 gene, especially a rare and potentially treatable Congenital Myasthenic Syndrome. The authors performed a detailed narrative review, including descriptions of the main pathophysiological, clinical, and therapeutic aspects of LRP4-related Congenital Myasthenic Syndromes.